219 related articles for article (PubMed ID: 21412332)
1. Translational medicine: Cancer lessons from mice to humans.
Tuveson D; Hanahan D
Nature; 2011 Mar; 471(7338):316-7. PubMed ID: 21412332
[No Abstract] [Full Text] [Related]
2. Implications of the new histological classification (WHO 2010) for pancreatic neuroendocrine neoplasms.
Crippa S; Partelli S; Boninsegna L; Falconi M
Ann Oncol; 2012 Jul; 23(7):1928. PubMed ID: 22753260
[No Abstract] [Full Text] [Related]
3. New target therapies for patients with neuroendocrine tumors of the pancreas.
Baltogiannis G; Katsios C; Roukos DH
Expert Rev Gastroenterol Hepatol; 2011 Oct; 5(5):563-6. PubMed ID: 21910571
[No Abstract] [Full Text] [Related]
4. Recent studies show promise for treating rare pancreatic tumors.
Peres J
J Natl Cancer Inst; 2011 Apr; 103(8):624-7. PubMed ID: 21474831
[No Abstract] [Full Text] [Related]
5. New treatments of pancreatic neuroendocrine tumors: why using them? How to use them?
Raymond E; Ruszniewski P
Target Oncol; 2012 Jun; 7(2):91-2. PubMed ID: 22669625
[No Abstract] [Full Text] [Related]
6. Advances in the treatment of pancreatic neuroendocrine tumours.
Gao F; Visvardis EE; Sita-Lumsden A; Waxman J
QJM; 2012 Sep; 105(9):819-22. PubMed ID: 22383691
[TBL] [Abstract][Full Text] [Related]
7. Systemic therapy for advanced pancreatic neuroendocrine tumors.
Kulke MH
Semin Oncol; 2013 Feb; 40(1):75-83. PubMed ID: 23391115
[TBL] [Abstract][Full Text] [Related]
8. Oral agents for treatment of patients with advanced pancreatic neuroendocrine tumors: could pharmaeconomic, cost-effectiveness data play a significant role?
Barna ME; Uomo I; Pastorello M
JOP; 2013 Jan; 14(1):102-4. PubMed ID: 23306347
[No Abstract] [Full Text] [Related]
9. Role of everolimus in pancreatic neuroendocrine tumors.
Goldstein R; Meyer T
Expert Rev Anticancer Ther; 2011 Nov; 11(11):1653-65. PubMed ID: 21932937
[TBL] [Abstract][Full Text] [Related]
10. Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.
Yim KL
Endocrine; 2011 Oct; 40(2):181-6. PubMed ID: 21870172
[TBL] [Abstract][Full Text] [Related]
11. Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors.
Naraev BG; Strosberg JR; Halfdanarson TR
Oncology; 2012; 83(3):117-27. PubMed ID: 22797357
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic NETs: where do we stand now?
Faivre S; Castellano D; Strosberg J; González E; Salazar R
Cancer Metastasis Rev; 2014 Mar; 33(1):361-6. PubMed ID: 24452757
[TBL] [Abstract][Full Text] [Related]
13. Advances in pancreatic neuroendocrine tumor treatment.
van der Veldt AA; Kleijn SA
N Engl J Med; 2011 May; 364(19):1873; author reply 1873-5. PubMed ID: 21561355
[No Abstract] [Full Text] [Related]
14. Novel agents in gastroenteropancreatic neuroendocrine tumors.
Stevenson R; Libutti SK; Saif MW
JOP; 2013 Mar; 14(2):152-4. PubMed ID: 23474560
[TBL] [Abstract][Full Text] [Related]
15. A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors.
Capdevila J; Tabernero J
Cancer Discov; 2011 Aug; 1(3):213-21. PubMed ID: 22586573
[TBL] [Abstract][Full Text] [Related]
16. Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors.
Liakakos T; Roukos DH
Future Oncol; 2011 Sep; 7(9):1025-9. PubMed ID: 21919689
[No Abstract] [Full Text] [Related]
17. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.
Peng L; Schwarz RE
Curr Mol Med; 2013 Mar; 13(3):333-9. PubMed ID: 23331005
[TBL] [Abstract][Full Text] [Related]
18. [Erlotinib, sunitinib, and everolimus].
Takahashi M
Nihon Rinsho; 2015 Mar; 73 Suppl 3():409-13. PubMed ID: 25857058
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States.
Casciano R; Chulikavit M; Perrin A; Liu Z; Wang X; Garrison LP
J Med Econ; 2012; 15 Suppl 1():55-64. PubMed ID: 22881362
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib in pancreatic neuroendocrine tumors.
Raymond E; Hammel P; Dreyer C; Maatescu C; Hentic O; Ruszniewski P; Faivre S
Target Oncol; 2012 Jun; 7(2):117-25. PubMed ID: 22661319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]